Alnylam Pharmaceuticals (ALNY) Cash from Operations (2009 - 2026)

Alnylam Pharmaceuticals has reported Cash from Operations for 18 years, with the latest figure at 70504000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 158.6% year-over-year to 70504000.0; the trailing twelve-month figure through Mar 2026 stood at 714896000.0 (up 1617.54% YoY), and the FY2025 full-year result was 524080000.0, up 6405.1% from the prior year.
• Cash from Operations for Q1 2026 stood at 70504000.0, down from 163555000.0 in the prior quarter.
• The five-year high for Cash from Operations was 359412000.0 in Q3 2023, with the low at 171193000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 8773764.71 across 5 years, with a median of 58986000.0 in 2023.
• Annual changes were most pronounced in 2024 — Cash from Operations slumped 217.71% — and 2025, when it surged 643.84%.
• Alnylam Pharmaceuticals' Cash from Operations stood at 131978000.0 in 2022, then soared by 77.42% to 29795000.0 in 2023, then tumbled by 217.71% to 94662000.0 in 2024, then jumped by 272.78% to 163555000.0 in 2025, then sank by 56.89% to 70504000.0 in 2026.
• The last three Cash from Operations figures came in at 70504000.0 (Q1 2026), 163555000.0 (Q4 2025), and 325109000.0 (Q3 2025), per Business Quant data.